Organization Overview
Alternative names
abemaciclib (verzenio) (1 trial)
aldesleukin (Proleukin) (1 trial)
anastrozole (arimidex) (4 trials)
atezolizumab (Tecentriq) (2 trials)
avelumab (bavencio) (3 trials)
bevacizumab (avastin) (6 trials)
bicalutamide (casodex) (2 trials)
carboplatin (paraplatin) (13 trials)
chlorambucil (Leukeran) (2 trials)
chlorhexidine (hibitane) (1 trial)
cisplatin (platinol) (20 trials)
docetaxel (taxotere) (3 trials)
doxorubicin (Doxil) (7 trials)
durvalumab (imfinzi) (2 trials)
epirubicin (ellence) (8 trials)
etoposide (vepesid) (4 trials)
exemestane (aromasin) (2 trials)
fludarabine (fludara) (1 trial)
fluorouracil (efudex) (8 trials)
fulvestrant (faslodex) (5 trials)
gemcitabine (gemzar) (9 trials)
gonadorelin (factrel) (1 trial)
interferon alpha-2b (Intron-A) (2 trials)
leuprolide (lupron) (2 trials)
mitomycin (mutamycin) (2 trials)
pazopanib (votrient) (1 trial)
pembrolizumab (keytruda) (17 trials)
prednisone (meticorten) (4 trials)
somatropin (protropin) (1 trial)
talimogene laherparepvec (Imlygic) (2 trials)
tamoxifen (nolvadex) (2 trials)
temsirolimus (torisel) (1 trial)
tremelimumab (Imjudo) (1 trial)
vinblastine (velban) (3 trials)
abiraterone (zytiga) (1 trial)
acetaminophen (tylenol) (1 trial)
afatinib (gilotrif) (2 trials)
alemtuzumab (campath) (1 trial)
bleomycin (blenoxane) (1 trial)
bortezomib (velcade) (1 trial)
decitabine (dacogen) (1 trial)
desflurane (suprane) (1 trial)
enzalutamide (xtandi) (1 trial)
erlotinib (tarceva) (2 trials)
ethosuximide (zarontin) (1 trial)
ibrutinib (imbruvica) (1 trial)
Inactivated Mycobacterium obuense (1 trial)
interferon alpha-2a (roferon-a) (1 trial)
ipilimumab (yervoy) (2 trials)
methylprednisolone (medrol) (3 trials)
mitoxantrone (novantrone) (1 trial)
olaparib (lynparza) (9 trials)
palbociclib (ibrance) (5 trials)
proanthocyanidin extract (1 trial)
radiolabeled albumin technetium Tc-99m albumin colloid kit (Microlite) (1 trial)
rituximab (rituxan) (3 trials)
romidepsin (istodax) (1 trial)
sargramostim (leukine) (1 trial)
temozolomide (temodar) (1 trial)
tisotumab vedotin (TIVDAK) (2 trials)
trastuzumab (herceptin) (1 trial)
Adenocarcinoma (Phase 3)
Adenocarcinoma of Lung (Phase 2)
Anus Neoplasms (Phase 2)
Brain Neoplasms (Phase 1)
Breakthrough Pain (Phase 3)
Breast Neoplasms (Phase 3)
Carcinoma (Phase 3)
Carcinoma, Lobular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Ovarian Epithelial (Phase 2)
Carcinoma, Renal Cell (Phase 3)
Carcinoma, Squamous Cell (Phase 3)
Central Nervous System Neoplasms (Phase 2)
Colonic Neoplasms (Phase 3)
Colorectal Neoplasms (Phase 3)
Communicable Diseases (Phase 3)
Digestive System Neoplasms (Phase 4)
Endometrial Neoplasms (Phase 2)
Enteropathy-Associated T-Cell Lymphoma (Phase 2)
Esophageal Neoplasms (Phase 2)
Esophageal Squamous Cell Carcinoma (Phase 2)
Fallopian Tube Neoplasms (Phase 3)
Fibrosis (Phase 2)
Gastrointestinal Neoplasms (Phase 4)
Glioma (Phase 2)
Head and Neck Neoplasms (Phase 3)
Histiocytoma, Malignant Fibrous (Phase 2)
Immunoblastic Lymphadenopathy (Phase 2)
Infections (Phase 3)
Kidney Neoplasms (Phase 3)
Laryngeal Neoplasms (Phase 2)
Leiomyosarcoma (Phase 2)
Leukemia (Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)
Leukemia, Lymphoid (Phase 3)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Leukemia, Myelomonocytic, Juvenile (Phase 2)
Long Term Adverse Effects (Phase 2)
Lung Neoplasms (Phase 3)
Lymphedema (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 2)
Medulloblastoma (Phase 2)
Melanoma (Phase 2)
Mesothelioma (Phase 3)
Microsatellite Instability (Phase 3)
Mucositis (Phase 2)
Multiple Myeloma (Phase 3)
Myelodysplastic Syndromes (Phase 3)
Nausea (Phase 3)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 2)
Neoplasms, Germ Cell and Embryonal (Phase 3)
Neoplasms, Plasma Cell (Phase 2)
Neoplasms, Second Primary (Phase 3)
Nervous System Neoplasms (Phase 2)
Neuroblastoma (Phase 3)
Neuroectodermal Tumors (Phase 2)
Neuroectodermal Tumors, Primitive (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Pathologic Processes (Phase 3)
Pelvic Neoplasms (Phase 2)
Peripheral Nervous System Diseases (Phase 2)
Pneumonia (Phase 3)
Postoperative Complications (Phase 3)
Preleukemia (Phase 2)
Prostatic Neoplasms (Phase 3)
Radiation Pneumonitis (Phase 2)
Rectal Neoplasms (Phase 3)
Recurrence (Phase 2)
Rhabdomyosarcoma (Phase 2)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Alveolar Soft Part (Phase 2)
Seminoma (Phase 3)
Small Cell Lung Carcinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 3)
Stomatitis (Phase 2)
Surgical Wound (Phase 3)
Surgical Wound Infection (Phase 3)
Teratoma (Phase 2)
Testicular Neoplasms (Phase 2)
Thoracic Neoplasms (Phase 1)
Triple Negative Breast Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Vaccinia (Phase 1)
Vomiting (Phase 3)
Wilms Tumor (Phase 3)
Wound Infection (Phase 3)
Wounds and Injuries (Phase 3)